Mark Levick, CEO of Alvotech says in a statement: “Teva is an ideal commercial partner for Alvotech and combines their leading commercial footprint and track record in the U.S. market with Alvotech’s scientific experience and state-of-the-art biologics manufacturing."
Alvotech is a fully integrated biopharmaceutical company focused on the development and manufacturing of biosimilar medicine. In the headquarters in Reykjavik, Iceland, Alvotech has cutting-edge in-house R&D capabilities, from cell line process and product development, through scale-up and manufacturing. Alvotech has attracted an international team of biopharmaceutical specialists.
Teva is a global leader in generic and specialty medicines with a portfolio of over 3,500 products in almost all therapeutic areas.